BIRC5在肝癌中的表达及其表达与临床病理特征的关系

Expression and Correlation of BIRC5 with Clinicopathological Features in Hepatocellular Carcinoma

目的探讨凋亡抑制蛋白BIRC5在肝癌中的表达及其表达与临床病理牲的关系。方法免疫组化检测BIRC5在20例正常肝组织及80例肝癌组织中的表达,分析其表达与临床病理特征的关系。结果 BIRC5在肝癌组织中的阳性表达率为66.3%,明显高于正常肝组织(5%),差异有统计学意义(P<0.05)。此外,BIRC5在低分化肝细胞癌中的表达率(83.3%)明显高于高-中分化肝细胞癌(55.4%);淋巴结转移患者中BIRC5的表达率(85.7%)明显高于无淋巴结转移患者(55.9%);II-III期患者BIRC5的表达率(83.9%)明显高于I期患者(57.1%),差异有统计学意义(P<0.05);而BIRC5表达率与年龄、性别、肿瘤最大直径无明显相关(P>0.05)。结论 BIRC5表达与肝癌的发生密切相关,可能成为肝癌诊断的新型标记物。

Objective To investigate the expression of apoptosis inhibitory protein BIRC5 and its relationship with clinicopathological features in hepatocellular carcinoma（HCC）. Methods The expression of BIRC5 was detected in 20 cases of normal liver tissues and 80 cases of hepatocellular carcinoma tissues by immunohistochemistry, then the relationship between BIRC5 expression and clinical pathological features was analyzed. Results The positive rate of BIRC5 expression in HCC was 66.3%, significantly higher than that in the normal liver tissue（5%）, with a statistically significant difference（P〈0.05）. In addition, the expression rate of BIRC5 in poorly differentiated hepatocellular carcinoma（83.3%） was significantly higher than that in well and moderately differentiated hepatocellular carcinoma（55.4%）; the expression rate of BIRC5 in patients with lymphatic metastasis（85.7%） was obviously higher than that in patients without lymphatic metastasis（55.9%）; the expression rate of BIRC5 in Ⅱ-Ⅲ stage of patients（83.9%） was significantly higher than that in Ⅰ stage of patients（57.1%）, the differences between two groups were statistically significant（P〈0.05）;moreover, the expression rate of BIRC5 has no significant correlations with age, gender and tumor diameter（P〈0.05）. Conclusion BIRC5 expression is closely related to the formation of HCC, which may be used as a new diagnostic marker.